Coronary Artery Disease Clinical Trial Space Intensifies with 20+ Companies in Active Development | DelveInsight
The coronary artery disease clinical trial analysis report delivers important insights into ongoing research of 20+ pipeline Coronary Artery Disease drugs, clinical strategies, upcoming therapeutics, and commercial analysis.
New York, USA, Sept. 30, 2026 (GLOBE NEWSWIRE) -- Coronary Artery Disease Clinical Trial Space Intensifies with 20+ Companies in Active Development | DelveInsight
The coronary artery disease clinical trial analysis report delivers important insights into ongoing research of 20+ pipeline Coronary Artery Disease drugs, clinical strategies, upcoming therapeutics, and commercial analysis.
DelveInsight’s 'Coronary Artery Disease Pipeline Insight 2026' report provides comprehensive global coverage of pipeline therapies for Coronary Artery Disease across various stages of clinical development. The report offers an in-depth analysis of key trends, emerging therapies, and competitive landscape dynamics, highlighting the strategies of major pharmaceutical companies to advance the pipeline and capitalize on future growth opportunities. In addition, it includes critical insights into clinical trial benchmarking, partnering and licensing activities, and regulatory pathways involving the FDA and EMA, enabling stakeholders to make informed decisions and optimize development strategies within the Coronary Artery Disease domain.
Coronary Artery Disease Clinical Trial Analysis Summary
- DelveInsight’s Coronary Artery Disease pipeline report depicts a robust space with 20+ active players working to develop 22+ pipeline Coronary Artery Disease drugs.
- Key Coronary Artery Disease companies, such as Beijing Inno Medicine Co., Ltd., Hexun Biosciences, XyloCor Therapeutics, Inc., Sirius Therapeutics, Abcentra, Roche, Verve Therapeutics, Inc., Suzhou Ribo Life Science, Amgen, Idorsia Pharmaceuticals, and others, are evaluating new Coronary Artery Disease drugs to improve the treatment landscape.
- Promising pipeline Coronary Artery Disease therapies, such as YN001, HeXell-2020, XC001, SRSD107, Orticumab, RO7763505, VERVE-102, RBD1119, RBD4059, Evolocumab, Selatogrel, and others, are in different phases of Coronary Artery Disease clinical trials.
- Approximately 4+ Coronary Artery Disease drugs are in the late stages of development.
- Notable MoAs in Coronary Artery Disease clinical trials include CD44 antigen inhibitors, HMG-CoA reductase inhibitors, Vascular endothelial growth factor replacements, Factor XI expression inhibitors, Anti-oxLDL, Cell replacements, and others.
Request a sample and discover the recent advances in Coronary Artery Disease treatment @ https://www.delveinsight.com/report-store/coronary-artery-disease-cad-pipeline-insight
What is Coronary Artery Disease?
Coronary Artery Disease (CAD) is a common type of heart disease that occurs when the coronary arteries become narrowed or blocked, primarily due to the buildup of fatty deposits called plaque. This process, known as atherosclerosis, can restrict blood flow and reduce the supply of oxygen to the heart muscle. CAD may develop gradually and can cause symptoms such as chest pain or pressure (angina), shortness of breath, fatigue, and reduced exercise tolerance. In severe cases, complete blockage of a coronary artery can lead to a heart attack. Major risk factors include high cholesterol, high blood pressure, diabetes, smoking, obesity, physical inactivity, and a family history of cardiovascular disease.
Find out more about treatment for Coronary Artery Disease @ Coronary Artery Disease New Treatment
A snapshot of the Pipeline Coronary Artery Disease Drugs mentioned in the report:
| Drugs | Company | Phase | MoA | RoA |
| YN001 | Beijing Inno Medicine Co., Ltd. | II | CD44 antigen inhibitors; HMG-CoA reductase inhibitors | IV infusion |
| XC001 | Xylocor Therapeutics | II | Vascular endothelial growth factor replacements | Injection |
| SRSD107 | Sirius Therapeutics | II | Factor XI expression inhibitors | SC |
| Orticumab | Abcentra | II | Anti-oxLDL | IV |
| HeXell-2020 | Hexun Biosciences | I/II | Cell replacements | IV |
| RO7763505 | Roche | I | Undefined mechanism | Oral |
Learn more about the Coronary Artery Disease research @ Coronary Artery Disease Clinical Trials
Arunima Dabral, Assistant Project Manager of Consulting and Competitive Intelligence, said that the CAD treatment landscape is evolving with increasing focus on addressing residual cardiovascular risk beyond conventional lipid-lowering and antithrombotic therapies. Emerging approaches targeting Lp(a), inflammation, plaque progression, and thrombosis are expected to expand treatment options for high-risk patients. The growing development of long-acting and genetically targeted therapies may further transform CAD management by enabling more durable risk reduction.
Recent Developments in Coronary Artery Disease Treatment Space
- In July 2026, Suzhou Ribo Life Science Co., Ltd. and Ribocure Pharmaceuticals AB announced positive results from a Phase IIa study evaluating vortosiran (RBD4059), an siRNA therapy targeting coagulation Factor XI (FXI), in patients with chronic coronary artery disease (CAD). The randomized, double-blind, placebo-controlled study demonstrated that vortosiran was generally well tolerated and achieved profound, dose-dependent, and sustained suppression of FXI activity in patients receiving standard-of-care aspirin treatment.
- In May 2026, Suzhou Ribo Life Science Co., Ltd. and Ribocure Pharmaceuticals AB announced the submission of a Phase II clinical trial application to the European Medicines Agency for RBD1119, an siRNA-based therapeutic being developed for the treatment of coronary artery disease. The submission marked an advancement of Ribo’s oligonucleotide-based therapeutic pipeline targeting thromboembolic and cardiovascular diseases.
- n March 2026, Sirius Therapeutics announced that the first patient had been dosed in a Phase II clinical trial of SRSD107, a next-generation, long-acting Factor XI (FXI)-targeting siRNA, in patients with chronic coronary and/or peripheral arterial disease. SRSD107 is being co-developed by Sirius Therapeutics and CRISPR Therapeutics as a potential treatment for cardiovascular and clotting-related diseases.
- In January 2025, XyloCor Therapeutics announced a USD 67.5 million Series B financing to advance the clinical development of XC001 (encoberminogene rezmadenovec), an investigational gene therapy for refractory angina associated with advanced coronary artery disease. The financing was intended to support a randomized, double-blind Phase IIb EXACT-2 trial evaluating XC001 through endocardial administration, as well as a separate Phase II trial evaluating XC001 as an adjunctive treatment to coronary artery bypass graft surgery.
- In August 2025, Abcentra LLC announced that the first patient had been dosed in the Phase IIb FORTIFY trial evaluating orticumab in patients with a history of type 1 myocardial infarction and elevated coronary inflammation. Orticumab is an investigational monoclonal antibody targeting oxidized LDL, and the company is developing it for secondary prevention of cardiac events following acute coronary syndrome.
Scope of the Coronary Artery Disease Pipeline Report
- Coverage: Global
- Coronary Artery Disease Therapeutic Assessment By Product Type: Mono, Combination, Mono/Combination
- Coronary Artery Disease Therapeutic Assessment By Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III
- Coronary Artery Disease Therapeutics Assessment By Route of Administration: Oral, Intravenous, Subcutaneous, Parenteral, Topical
- Coronary Artery Disease Therapeutics Assessment By Molecule Type: Recombinant fusion proteins, Small molecule, Monoclonal antibody, Peptide, Polymer, Gene therapy
- Coronary Artery Disease Therapeutics Assessment By Mechanism of Action: CD44 antigen inhibitors, HMG-CoA reductase inhibitors, Gene transference, Vascular endothelial growth factor replacements, Factor XI expression inhibitors, Immunomodulators, LDL receptor antagonists, RNA interference, Cell replacements, and others
- Key Coronary Artery Disease Companies: Beijing Inno Medicine Co., Ltd., Hexun Biosciences, XyloCor Therapeutics, Inc., Sirius Therapeutics, Abcentra, Roche, Verve Therapeutics, Inc., Suzhou Ribo Life Science, Amgen, Idorsia Pharmaceuticals, and others.
- Key Coronary Artery Disease Pipeline Therapies: YN001, HeXell-2020, XC001, SRSD107, Orticumab, RO7763505, VERVE-102, RBD1119, RBD4059, Evolocumab, Selatogrel, and others.
Dive deep into rich insights for Coronary Artery Disease cure, visit @ Coronary Artery Disease News
Table of Contents
| 1. | Coronary Artery Disease Pipeline Report Introduction |
| 2. | Coronary Artery Disease Pipeline Report Executive Summary |
| 3. | Coronary Artery Disease Pipeline: Overview |
| 4. | Analytical Perspective In-depth Commercial Assessment |
| 5. | Coronary Artery Disease Clinical Trial Therapeutics |
| 6. | Coronary Artery Disease Pipeline: Late-Stage Products (Pre-registration) |
| 7. | Coronary Artery Disease Pipeline: Late-Stage Products (Phase III) |
| 8. | Coronary Artery Disease Pipeline: Mid-Stage Products (Phase II) |
| 9. | Coronary Artery Disease Pipeline: Early-Stage Products (Phase I) |
| 10. | Coronary Artery Disease Pipeline Therapeutics Assessment |
| 11. | Inactive Products in the Coronary Artery Disease Pipeline |
| 12. | Company-University Collaborations (Licensing/Partnering) Analysis |
| 13. | Key Companies |
| 14. | Key Products in the Coronary Artery Disease Pipeline |
| 15. | Unmet Needs |
| 16. | Market Drivers and Barriers |
| 17. | Future Perspectives and Conclusion |
| 18. | Analyst Views |
| 19. | Appendix |
For further information on the Coronary Artery Disease clinical trials, reach out @ Coronary Artery Disease Medication
Related Reports
Coronary Artery Disease Market
Coronary Artery Disease Market Insights, Epidemiology, and Market Forecast – 2036 report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key Coronary Artery Disease companies, including Cytokinetics, Novo Nordisk, BioCardia, Cardurion Pharmaceuticals, Bayer, AstraZeneca, Boehringer Ingelheim, Mesoblast, AskBio, and others.
Coronary Artery Disease Treatment Devices Market
Coronary Artery Disease Treatment Devices Market Insights, Competitive Landscape, and Market Forecast – 2034 report deliver an in-depth understanding of the disease, historical and forecasted epidemiology, market share of the individual therapies, and key CHF treatment devices companies, including GE HealthCare, Boston Scientific Corporation, Medtronic, Abbott, Biotronik SE & Co. KG, LivaNova PLC, Shree Pacetronix Ltd., OSCOR Inc., MEDICO S.p.A., Lepu Medical Technology Co. Ltd., MicroPort Scientific Corporation, Edwards Lifesciences, Zoll Medical Corporation, Vitatron, Osypka Medical, Inc., Cook, CorWave SA, Berlin Heart GmbH, Jarvik Heart, Inc., and others.
Chronic Heart Failure Market Insights, Epidemiology, and Market Forecast – 2036 report delivers an in-depth understanding of the market trends, market drivers, market barriers, and key chronic heart failure companies, including Cytokinetics, Bayer, Eli Lilly, BioCardia, Mesoblast, Tenax Therapeutics, Novo Nordisk, AstraZeneca, Boehringer Ingelheim, Bristol Myers Squibb, Intra-Cellular Therapies, Cardurion Pharmaceuticals, Rivus Pharmaceuticals, and others.
Acute Heart Failure Market Insights, Epidemiology, and Market Forecast – 2036 report delivers an in-depth understanding of the market trends, market drivers, market barriers, and key acute heart failure companies, including Arena Pharmaceuticals, AstraZeneca, Palatin Technologies, Inc, Boehringer Ingelheim, Eli Lilly and Company, Aventyn, Inc., Corthera, Inc, Idorsia Pharmaceuticals Ltd., The Medicines Company, Bristol-Myers Squibb, Cardioxyl Pharmaceuticals, Inc, Nile Therapeutics, Trevena Inc., Scios, Inc., Novartis, and others.
Advanced Heart Failure Market Insights, Epidemiology, and Market Forecast – 2036 report delivers an in-depth understanding of the market trends, market drivers, market barriers, and key advanced heart failure companies, including Sana Biotechnology, Salubris Biotherapeutics, Roche, Rivus Pharmaceuticals, Ribomic, Renova Therapeutics, Relaxera, and others.
About DelveInsight
DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance. Get hassle-free access to all the healthcare and pharma market research reports through our subscription-based platform PharmDelve.
Contact Us Shruti Thakur info@delveinsight.com +14699457679
Legal Disclaimer:
EIN Presswire provides this news content "as is" without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author above.
